- This Week in Biopharma Deals, by biodealroom
- Posts
- Novo isn't the only company in Denmark 😉
Novo isn't the only company in Denmark 😉
Week 42 Deals (2024)
Deal of the Week: Lundbeck & Longboard (Source)
Lundbeck expands its neuroscience pipeline through acquisition
Structure: Lundbeck will acquire Longboard Pharmaceuticals
Date Announced: October 13, 2024
Total Deal Value: $650 million
Upfront Cash: $200 million
Total Milestones: $450 million
Royalties: Tiered royalties on net sales (undisclosed rates)
Other Terms: Lundbeck will gain access to Longboard's investigational therapies for neurological disorders, including a promising treatment for Dravet syndrome
Notable Deals
Exelixis & Merck (Source)
Collaboration to evaluate zanzalintinib with KEYTRUDA® and WELIREG® in cancer trials
Structure: Clinical development collaboration
Date Announced: October 11, 2024
Viatris & Lexicon Pharmaceuticals (Source)
Viatris secures global rights to sotagliflozin outside the U.S. and Europe
Structure: Exclusive licensing agreement
Date Announced: October 16, 2024
Total Deal Value: Up to $325 million
Upfront Cash: $25 million
Total Milestones: Undisclosed regulatory and sales milestones
Royalties: Tiered royalties ranging from low-double-digit to upper-teens on annual net sales